Asia Executives On The Move: Merck, Novo Nordisk, Ascentage
Executive Summary
Merck China R&D head leaving after overseeing several high-profile drug approvals, while Novo Nordisk China's marketing head will lead the firm's operations in Oceania.
You may also be interested in...
Coronavirus Vaccines As A Public Good: How Reasonable Is Reasonable?
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.
China Regulatory Express: Biosecurity Law, Export Controls And The Life Science Sector
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Need a specific report? 1000+ reports available
Buy Reports